EXTENDED REPORT

Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology

X Le Loët¹, J M Berthelot², A Cantagrel³, B Combe⁴, M De Bandt⁵, B Fautrel⁶, R M Flipo⁷, F Lioté⁸, J F Maillefert⁹, O Meyer¹⁰, A Saraux¹¹, D Wendling¹², F Guillemin¹³

¹ Department of Rheumatology, Rouen University Hospital, Rouen, France
² Department of Rheumatology, Nantes University Hospital, Nantes, France
³ Department of Rheumatology, Toulouse University Hospital, Toulouse, France
⁴ Federation of Rheumatology, Montpellier University Hospital, Montpellier, France
⁵ Department of Rheumatology, Bichat Paris University Hospital, Paris, France
⁶ Department of Rheumatology, La Pitié Paris University Hospital, Paris
⁷ Department of Rheumatology, Lille University Hospital, Lille, France
⁸ Department of Rheumatology, Lariboisière Paris University Hospital, Paris
⁹ Department of Rheumatology, Dijon University Hospital, Dijon, France
¹⁰ Department of Rheumatology, Bichat Paris University Hospital
¹¹ Department of Rheumatology, Brest University Hospital, Brest, France
¹² Department of Rheumatology, Besançon University Hospital, Besançon, France
¹³ EA 344, Department of Public Health, Nancy University Hospital, Nancy, France

Correspondence to:
Professor Xavier Le Loët
Service de Rhumatologie, CHU–Hôpitaux de Rouen, 1 rue de Germont, 76031 Rouen Cedex, France; xavier.le-loet{at}chu-rouen.fr

Objective: To elaborate a clinical practice decision tree for the choice of the first disease modifying antirheumatic drug (DMARD) for untreated rheumatoid arthritis of less than six months’ duration.

Methods: Four steps were employed: (1) review of published reports on DMARD efficacy against rheumatoid arthritis; (2) inventory of the information available to guide DMARD choice; (3) selection of the most pertinent information by 12 experts using a Delphi method; and (4) choice of DMARDs in 12 clinical situations defined by items selected in step 3 (28 joint disease activity score (DAS 28): 3.2; >3.2 and 5.1; >5.1; rheumatoid factor status (positive/negative); structural damage (with/without)—that is, 3x2x2). Thus, multiplied by all the possible treatment pairs, 180 scenarios were obtained and presented to 36 experts, who ranked treatment choices according to the Thurstone pairwise method.

Results: Among the 77 items identified, 41 were selected as pertinent to guide the DMARD choice. They were reorganised into five domains: rheumatoid arthritis activity, factors predictive of structural damage; patient characteristics; DMARD characteristics; physician characteristics. In the majority of situations, the two top ranking DMARD choices were methotrexate and leflunomide. Etanercept was an alternative for these agents when high disease activity was associated with poor structural prognosis and rheumatoid factor positivity.

Conclusions: Starting with simple scenarios and using the pairwise method, a clinical decision tree could be devised for the choice of the first DMARD to treat very early rheumatoid arthritis.

Abbreviations: DAS 28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug

Keywords: decision tree; early rheumatoid arthritis; DMARD choice

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Bansard, C., Lequerre, T., Daveau, M., Boyer, O., Tron, F., Salier, J.-P., Vittecoq, O., Le-Loet, X. (2009). Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted?. Rheumatology (Oxford) 48: 1021-1028 [Abstract] [Full Text]  
• Trocme, C, Marotte, H, Baillet, A, Pallot-Prades, B, Garin, J, Grange, L, Miossec, P, Tebib, J, Berger, F, Nissen, M J, Juvin, R, Morel, F, Gaudin, P (2009). Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 68: 1328-1333 [Abstract] [Full Text]  
• HERSH, A., YAZDANY, J. (2009). Clinical Practice Guidelines and Diagnostic Uncertainty in the Management of Early Rheumatoid Arthritis. The Journal of Rheumatology 36: 863-864 [Full Text]  
• BENHAMOU, M., RINCHEVAL, N., ROY, C., FOLTZ, V., ROZENBERG, S., SIBILIA, J., SCHAEVERBEKE, T., BOURGEOIS, P., RAVAUD, P., FAUTREL, B. (2009). The Gap Between Practice and Guidelines in the Choice of First-line Disease Modifying Antirheumatic Drug in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort. The Journal of Rheumatology 36: 934-942 [Abstract] [Full Text]